LDLR-Related Familial Hypercholesterolemia: Disease Characteristics Report

Scope. This report focuses narrowly on familial hypercholesterolemia caused by pathogenic germline variants in LDLR, rather than the broader clinical FH phenotype caused by APOB, PCSK9, LDLRAP1, polygenic hypercholesterolemia, or secondary dyslipidemia. Evidence is predominantly aggregated disease-level literature, expert guidance, and trial registries; it is not an analysis of individual EHR records.

The following table provides an ontology-ready synopsis.

Table: This table condenses the main disease-knowledge-base domains for LDLR-related familial hypercholesterolemia into ontology-ready findings and quantitative anchors. It is useful as a compact reference for curation and downstream structured annotation. (arnold2023familialhypercholesterolemiapitfalls pages 1-2, chora2022theclinicalgenome pages 5-6, watts2023internationalatherosclerosissociety pages 1-2, chora2022theclinicalgenome pages 8-10, ishibashi1993hypercholesterolemiainlow pages 1-2, arnold2023familialhypercholesterolemiapitfalls pages 4-6, arnold2023familialhypercholesterolemiapitfalls pages 2-3, sato2023generationofa pages 1-2, xiao2024efficacyandsafety pages 1-2)

1. Disease information

Definition. LDLR-related familial hypercholesterolemia (LDLR-FH) is a lifelong Mendelian disorder of hepatic LDL-particle clearance. One pathogenic allele usually causes heterozygous FH (HeFH); two pathogenic alleles—homozygous or compound heterozygous—cause the substantially more severe homozygous phenotype (HoFH). LDL-C is elevated from birth, producing cumulative arterial cholesterol exposure and premature atherosclerotic cardiovascular disease (ASCVD). The IAS describes FH as a highly penetrant, co-dominant disorder affecting the hepatic LDL-clearance pathway. (arnold2023familialhypercholesterolemiapitfalls pages 1-2, watts2023internationalatherosclerosissociety pages 1-2)

Identifiers and synonyms. Recommended knowledge-base identifiers are MONDO:0007750 (“hypercholesterolemia, familial, 1”; LDLR-associated entity), broader MONDO:0005439 (“familial hypercholesterolemia”), OMIM #143890 (“Hypercholesterolemia, familial, 1”), ORPHA:391665 (familial hypercholesterolemia), MeSH D006938, US ICD-10-CM E78.01, and ICD-11 familial hypercholesterolaemia under the disorders-of-lipoprotein-metabolism hierarchy. Because coding-system releases differ, the ICD-11 code should be version-validated before production use. Open Targets independently identifies LDLR as the highest-scoring target for familial hypercholesterolemia and links it to MONDO:0005439 and MONDO:0007750. (OpenTargets Search: familial hypercholesterolemia-LDLR)

Common names include LDLR-related FH, familial hypercholesterolemia type 1, autosomal dominant hypercholesterolemia type 1, LDL receptor deficiency, HeFH, and LDLR-associated HoFH. “Autosomal dominant” is clinically familiar, although “autosomal co-dominant” better captures the allele-dose phenotype.

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a germline pathogenic or likely pathogenic LDLR variant that reduces receptor abundance or function. LDLR accounts for approximately 80–90% of genetically diagnosed FH, although the percentage depends on referral and testing criteria. The downstream defect is reduced hepatocyte uptake of apoB-containing LDL, prolonged plasma LDL residence, and lifelong hypercholesterolemia. (arnold2023familialhypercholesterolemiapitfalls pages 1-2, xiao2024efficacyandsafety pages 1-2)

Risk factors and modifiers

• Genetic severity: two affected alleles, null alleles, and lower residual receptor activity produce higher LDL-C and earlier disease. A classic FH variant plus LDL-C >190 mg/dL confers about 3.7-fold greater CHD risk than the same LDL-C without an identified FH variant, and up to approximately 20–22-fold risk relative to normolipidemic/non-carrier comparators in cited cohorts. (arnold2023familialhypercholesterolemiapitfalls pages 2-3, xiao2024efficacyandsafety pages 1-2)
• Additional inherited risk: elevated LPA/Lp(a), polygenic LDL-C burden, and variants influencing apoB lipoprotein production or clearance modify expression. Lp(a) >50 mg/dL combined with FH denotes particularly high myocardial-infarction risk; conversely, Lp(a)-cholesterol can inflate measured LDL-C and mimic clinical FH. In one Copenhagen analysis, high Lp(a) contributed to approximately 25% of clinical FH classifications; Lp(a)-adjustment moved 16.6% of patients to a lower Dutch Lipid Clinic Network category. (arnold2023familialhypercholesterolemiapitfalls pages 4-6)
• Environmental/clinical amplifiers: smoking, hypertension, diabetes, obesity, physical inactivity, diets rich in saturated/trans fats, chronic kidney disease, and delayed or inadequate LDL-lowering increase absolute ASCVD risk. Age represents cumulative exposure rather than disease acquisition.
• Sex: inheritance is not sex-linked and the birth ratio should be approximately equal. Premenopausal estrogen may delay clinical events in women, but LDL elevation is present in both sexes from birth.

Protective factors

Protective factors do not remove the causal allele. They reduce LDL burden or downstream risk: early sustained LDL-C lowering, absence of smoking, healthy blood pressure and glycemia, physical activity, healthy weight, and substitution of unsaturated for saturated fat. Genetic PCSK9 or ANGPTL3 loss-of-function can lower apoB lipoproteins; PCSK9 loss-of-function is protective against coronary disease mechanistically, although it is not a routine modifier test in LDLR-FH. (srivastava2023areviewof pages 8-9)

Gene–environment interaction: diet has a modest effect relative to the LDLR defect, but high-fat/high-cholesterol exposure magnifies hyperlipidemia and atherosclerosis. LDLR-knockout mice illustrate this interaction: dietary cholesterol causes a marked IDL/LDL rise, whereas the normal-diet mouse phenotype is milder than human HoFH because murine lipoprotein physiology differs. (ishibashi1993hypercholesterolemiainlow pages 1-2, sato2023generationofa pages 1-2)

3. Phenotypes

Physical stigmata are insensitive screening features: their absence does not exclude FH. Contemporary treatment may further reduce their frequency. (arnold2023familialhypercholesterolemiapitfalls pages 2-3)

Quality of life. Most children and many adults are asymptomatic, but diagnosis imposes lifelong medication, dietary vigilance, family testing, and anxiety about premature events. HoFH adds frequent apheresis, venous-access burden, xanthomas, repeated imaging, and early cardiovascular procedures. Robust phenotype-specific EQ-5D/SF-36 estimates were not available in the retrieved primary evidence; this field should therefore be recorded as evidence limited, not “no impact.”

4. Genetic and molecular information

Gene. LDLR—HGNC:6547; NCBI Gene:3949; Ensembl ENSG00000130164; chromosome 19p13.2—encodes the low-density lipoprotein receptor. The disease alleles are germline. Somatic LDLR variation is not the cause of inherited FH.

Variant spectrum. More than 2,300 unique FH-associated LDLR variants were already known when ClinGen issued its LDLR-specific ACMG/AMP rules. Variants include missense (the largest group), nonsense, frameshift, canonical and noncanonical splice variants, in-frame indels, promoter changes, and exon/whole-gene deletions or duplications. Frameshifts account for about 20% of associated variants. Stop variants before amino acid 830 remove the NPXY-containing cytoplasmic tail needed for internalization and meet strong loss-of-function logic. (chora2022theclinicalgenome pages 5-6, chora2022theclinicalgenome pages 1-3)

Functional classes. The traditional receptor classes are: I, absent synthesis; II, defective ER-to-Golgi transport; III, defective LDL binding; IV, defective clustering/internalization; V, defective endosomal dissociation/recycling; and sometimes VI, defective basolateral targeting. These converge on loss of LDL uptake. Null alleles generally have <2% activity; clinical trials often operationalize null as <15% activity, emphasizing that thresholds vary by context. (NCT04233918 chunk 1)

Classification. Use five-tier ACMG/AMP categories—pathogenic, likely pathogenic, VUS, likely benign, benign—with ClinGen FH Variant Curation Expert Panel specifications. These modify population-frequency thresholds using gnomAD PopMax, define PVS1-eligible loss-of-function alleles, calibrate functional assays and computational evidence, and specify case/segregation evidence. Examples include PM1 for rare missense substitutions in exon 4 or one of 60 conserved cysteines; PP4 for a rare variant in a patient meeting DLCN ≥6, Simon Broome, or MEDPED criteria; and PP1_Strong for at least six informative cosegregating meioses. A 54-variant pilot produced 6 benign, 2 likely benign, 18 VUS, 15 likely pathogenic, and 13 pathogenic classifications with complete panel agreement. (chora2022theclinicalgenome pages 8-10, chora2022theclinicalgenome pages 11-13)

Allele frequency. A universal frequency cannot be supplied because LDLR-FH comprises thousands of alleles. Most pathogenic variants are individually rare or absent in gnomAD; founder alleles can be locally enriched. Report variant-specific gnomAD ancestry frequency and homozygote count, not an aggregate disease frequency. Examples of founder enrichment occur in French Canadians, Lebanese, Afrikaners, Christian Lebanese, and several European isolates.

Modifiers and epigenetics. LPA, common polygenic LDL-C alleles, APOE, PCSK9, ANGPTL3, and genes affecting apoB production/clearance can modify phenotype. No reproducible disease-defining methylation or histone signature currently replaces DNA diagnosis. Epigenetic and transcriptomic changes observed in atherosclerotic plaque are predominantly downstream consequences of lipid exposure and inflammation.

Structural abnormalities. LDLR exon-level deletions/duplications are clinically important copy-number variants. Balanced translocations, aneuploidy, repeat expansions, and mitochondrial variants are not standard causes of LDLR-FH.

5. Environmental and lifestyle information

LDLR-FH is not caused by toxins, radiation, occupational exposure, or infection. Diet, exercise, adiposity, tobacco, alcohol-related metabolic effects, blood pressure, and diabetes modify cardiovascular expression. A heart-healthy diet and exercise are recommended adjuncts but rarely normalize genetically elevated LDL-C. Infectious agents and vaccination have no disease-specific etiologic role.

Secondary causes that can worsen or mimic the biochemical phenotype include hypothyroidism, nephrotic syndrome, cholestatic liver disease, uncontrolled diabetes, obesity, and LDL-raising drugs. These should be addressed before assigning pathogenicity evidence or a definitive clinical diagnosis. ClinGen explicitly requires exclusion of alternative hypercholesterolemia causes. (chora2022theclinicalgenome pages 8-10)

6. Mechanism and pathophysiology

Causal chain: germline LDLR loss-of-function → reduced hepatocyte surface LDLR or impaired binding/internalization/recycling → slower removal of apoB-100 LDL and remnant particles → elevated plasma LDL-C from birth → arterial intimal entry and proteoglycan retention → oxidation/aggregation and endothelial activation → monocyte recruitment and macrophage foam cells → chronic inflammatory plaque growth, necrotic core and calcification → coronary ischemia, MI, aortic-root disease, stroke, or peripheral disease.

The LDLR normally undergoes clathrin-mediated endocytosis and recycling. PCSK9 binding diverts LDLR toward lysosomal degradation; statins and ezetimibe induce residual LDLR through intracellular cholesterol depletion, whereas PCSK9 antibodies or inclisiran preserve residual receptor. Consequently, these therapies work best when some LDLR function remains. ANGPTL3 inhibition, lomitapide, and apheresis act substantially independently of LDLR and are especially important in null/null HoFH. (srivastava2023areviewof pages 8-9, arnold2023familialhypercholesterolemiapitfalls pages 4-6)

Tissues/cells: hepatocytes are the upstream causal cell; arterial endothelial cells, smooth-muscle cells, monocyte-derived macrophages, and valve interstitial cells mediate downstream injury. Suggested terms include GO:0006898 receptor-mediated endocytosis, GO:0034383 low-density lipoprotein particle clearance, GO:0042157 lipoprotein metabolic process, GO:0006954 inflammatory response, GO:0045766 positive regulation of angiogenesis/vascular remodeling as context-appropriate; CL:0000182 hepatocyte, CL:0000115 endothelial cell, CL:0000235 macrophage, and CL:0000192 smooth-muscle cell.

Subcellular terms: plasma membrane (GO:0005886), clathrin-coated pit (GO:0005905), endosome (GO:0005768), lysosome (GO:0005764), and endoplasmic reticulum (GO:0005783). The biochemical abnormality is receptor dysfunction rather than an enzyme or ion-channel deficiency.

Molecular profiling. Routine diagnosis does not require transcriptomics, proteomics, metabolomics, single-cell, or spatial profiling. Lipidomics shows excess apoB-containing cholesterol-rich particles, while plaque single-cell/spatial studies illuminate downstream atherosclerosis rather than uniquely identifying LDLR-FH. Functional LDL uptake and cell-surface-expression assays are most useful for resolving VUS. In-silico prediction alone is insufficient; functional characterization or informative cascade segregation is preferred. (chora2022theclinicalgenome pages 1-3)

Advanced technology. Preclinical base/gene-editing strategies targeting PCSK9 or ANGPTL3 achieved up to 90% PCSK9 and 60% LDL reduction for eight months in nonhuman primates; ANGPTL3 suppression exceeded 95% for up to two years in cited preclinical work. LDLR-enhancing strategies require a usable allele, whereas ANGPTL3 editing is potentially LDLR-independent. These are experimental and do not establish long-term human safety. (srivastava2023areviewof pages 14-16)

7. Anatomical structures affected

The liver is the primary mechanistic organ because hepatic LDLR controls most plasma LDL clearance (UBERON:0002107). Secondary injury involves coronary arteries, aorta/aortic root, aortic valve, carotid and peripheral arteries, myocardium after ischemia, tendons, skin/eyelids, and cornea. Suggested mappings include heart UBERON:0000948, liver UBERON:0002107, coronary artery UBERON:0001621, aorta UBERON:0000947, aortic valve UBERON:0002137, Achilles tendon UBERON:0000979, cornea UBERON:0000964, and skin UBERON:0002097. Disease is systemic rather than lateralized.

8. Temporal development

LDL-C elevation is congenital, chronic, and lifelong. HeFH is frequently asymptomatic through childhood; subclinical atherosclerosis accumulates before adult coronary events. HoFH can produce childhood xanthomas, aortic and coronary disease, and occasionally fatal cardiovascular events in childhood or infancy when receptor activity is nearly absent. (sato2023generationofa pages 1-2)

A practical course model is: (1) biochemical disease from birth; (2) subclinical arterial dysfunction/intima-media or plaque burden; (3) overt xanthomas/aortic or coronary disease; (4) recurrent ASCVD/heart failure or procedural burden. There is no spontaneous remission. LDL-C reduction is treatment-induced; plaques and xanthomas can stabilize or regress with intensive therapy, but the genotype remains. The critical intervention window is childhood, before cumulative LDL exposure produces irreversible plaque.

9. Inheritance and population

LDLR-FH is autosomal co-dominant. An affected heterozygous parent transmits the variant to 50% of offspring. Two affected parents can have children with biallelic disease; reproductive risk depends on both parental genotypes. Penetrance for elevated LDL-C is high but age-dependent penetrance for ASCVD is incomplete and modified by treatment and other risk factors. Expressivity is variable; anticipation is not expected. Germline mosaicism is possible in principle but is not a characteristic feature. Consanguinity increases biallelic disease risk where the same founder allele circulates.

Best contemporary estimates are approximately 1 in 311 people for FH globally—about 35 million individuals—and roughly 1 in 250–300 in many populations. HoFH is approximately 1 in 250,000–360,000; one 2023 review cited 1 in 300,000. Prevalence rises to approximately 1 in 17 among people with premature ASCVD. Only about 10% are diagnosed worldwide, and >80% of treated patients fail to achieve recommended LDL-C goals. Incidence is rarely reported because the condition is congenital; under stable population assumptions, birth incidence approximates prevalence. (watts2023internationalatherosclerosissociety pages 1-2, arnold2023familialhypercholesterolemiapitfalls pages 2-3, xiao2024efficacyandsafety pages 1-2)

Both sexes and all ancestries are affected. Regional variation chiefly reflects founder effects, ascertainment, access to testing, and diagnostic infrastructure—not environmental endemicity.

10. Diagnostics

Core tests: fasting or nonfasting lipid profile, repeat LDL-C confirmation, apoB, triglycerides, liver/renal/thyroid tests to exclude secondary causes, and Lp(a) for risk and LDL-C interpretation. Opportunistic adult evaluation is recommended at LDL-C ≥190 mg/dL; age-, sex-, and country-specific >95th-percentile values are preferred for population screening. If triglycerides exceed 400 mg/dL, obtain a fasting sample and direct LDL-C measurement. (watts2023internationalatherosclerosissociety pages 2-3)

Clinical criteria: Dutch Lipid Clinic Network, Simon Broome, and MEDPED combine LDL-C, premature ASCVD, family history, xanthomas/arcus, and genotype. Their sensitivity varies by setting; one mutation-positive analysis reported sensitivities of only 9% for DLCN ≥6, 17% for Simon Broome, and 31% for MEDPED, supporting genetic confirmation where feasible. (arnold2023familialhypercholesterolemiapitfalls pages 2-3)

Genetic approach: sequence LDLR, APOB, and PCSK9 at minimum, usually through an FH/dyslipidemia panel; add deletion/duplication analysis because LDLR CNVs are relevant. Broader panels may include LDLRAP1, ABCG5, ABCG8, and LIPA for phenocopies. A known familial LDLR variant should be tested directly in relatives. WES/WGS are useful after negative panel testing, for structural/noncoding variants or blended phenotypes, but are not obligatory first-line tests. CMA, karyotype, FISH, mtDNA, and repeat-expansion testing are not routine. A VUS does not confirm FH or justify predictive testing without additional evidence.

Imaging/risk assessment: ECG and stress testing evaluate suspected ischemia; coronary CT angiography, carotid ultrasound, echocardiography, and aortic-root/valve imaging are used according to age, severity, symptoms, and HoFH status. Biopsy is unnecessary.

Differential diagnosis: polygenic hypercholesterolemia; APOB- or PCSK9-related AD FH; recessive LDLRAP1 hypercholesterolemia; sitosterolemia (ABCG5/ABCG8; elevated plant sterols); lysosomal acid lipase deficiency (LIPA; hepatic disease); familial combined hyperlipidemia; dysbetalipoproteinemia; high Lp(a); and secondary hypercholesterolemia.

Screening: IAS gives Class 1 recommendations for multiple detection strategies, selective screening in premature ASCVD, and cascade testing of close relatives using genotype plus phenotype. Universal pediatric screening followed by reverse cascade testing is reasonable; at-risk HeFH children should be tested around age five—or age two with a strong premature-ASCVD history—while suspected HoFH should be evaluated at birth or by age two. Combined cascade and young-age universal screening could identify >90% of cases if effectively implemented. (watts2023internationalatherosclerosissociety pages 1-2, watts2023internationalatherosclerosissociety pages 2-3)

11. Outcome and prognosis

Untreated LDLR-FH causes progressive premature ASCVD and excess cardiovascular mortality. Prognosis depends principally on cumulative LDL-C exposure, residual receptor activity, number/type of alleles, Lp(a), smoking, diabetes, blood pressure, established ASCVD, age at treatment, adherence, and achieved LDL-C. HoFH—particularly null/null disease—has the poorest untreated prognosis.

There is no meaningful universal “five-year survival” statistic analogous to oncology because modern outcome depends strongly on genotype, ascertainment age, and treatment. Early sustained statin-based therapy markedly improves outlook; intensive combination therapy can cause xanthoma disappearance and plaque stabilization/regression. Nevertheless, fewer than 3% reached guideline LDL targets in one reviewed global context, illustrating persistent morbidity risk. (arnold2023familialhypercholesterolemiapitfalls pages 1-2, arnold2023familialhypercholesterolemiapitfalls pages 7-8)

Complications include MI, coronary revascularization, ischemic cardiomyopathy, aortic stenosis/root disease, stroke, peripheral arterial disease, and recurrent events. Functional disability is secondary to these complications and, in HoFH, treatment burden. Prognostic biomarkers include achieved and cumulative LDL-C, apoB, Lp(a), coronary plaque burden, and presence of a pathogenic/null LDLR genotype.

12. Treatment

Strategy. Begin lifestyle therapy and pharmacologic LDL lowering early. For most HeFH: maximally tolerated high-intensity statin → add ezetimibe → add a PCSK9 monoclonal antibody or inclisiran; bempedoic acid is an option for additional lowering or statin intolerance. LDL goals cited by ESC/EAS are ≥50% reduction and <70 mg/dL without major additional risk, or <55 mg/dL with ASCVD/another major risk factor. (arnold2023familialhypercholesterolemiapitfalls pages 4-6)

• Statins inhibit HMG-CoA reductase and upregulate residual LDLR: approximately 50–60% LDL-C reduction with high-potency monotherapy. Ezetimibe inhibits NPC1L1; combination may achieve roughly 65–70%. Suggested NCIt: Statin (C1655 class), Atorvastatin (C28837), Rosuvastatin, Ezetimibe (C61731). (arnold2023familialhypercholesterolemiapitfalls pages 4-6)
• Bempedoic acid, an ACLY inhibitor activated mainly in liver, reduced LDL-C by 22.3% in a pooled 112-person clinical-HeFH subgroup. Hyperuricemia/gout and tendon injury are recognized concerns. (arnold2023familialhypercholesterolemiapitfalls pages 4-6)
• Alirocumab/evolocumab prevent PCSK9-mediated LDLR degradation and reduce LDL-C approximately 45–65% in HeFH trials. Response is weak or absent with no functional receptor. A 2024 pediatric meta-analysis of nine studies found LDL-C −37.92% (95% CI −43.06 to −32.78), apoB −33.67%, and Lp(a) −16.94%; agents were generally well tolerated. (arnold2023familialhypercholesterolemiapitfalls pages 4-6, xiao2024efficacyandsafety pages 1-2)
• Inclisiran is hepatocyte-targeted siRNA that suppresses PCSK9 synthesis. ORION-9 (NCT03397121) was a completed phase III randomized double-blind trial in 482 adults with HeFH, dosing on days 1 and 90 and then every six months. ORION-16 (NCT04652726) enrolled 141 adolescents in a completed phase III study. (NCT03397121 chunk 1, NCT04652726 chunk 1)
• Evinacumab, an ANGPTL3 antibody, is LDLR-independent and lowers HoFH LDL-C by approximately 50%, including about 43% in null/null patients. The pivotal completed phase III trial NCT03399786 randomized 65 HoFH patients; pediatric NCT04233918 was a completed phase Ib/III single-arm study of 20 children. Suggested NCIt: Evinacumab (C158502). (arnold2023familialhypercholesterolemiapitfalls pages 7-8, NCT04233918 chunk 1, NCT03399786 chunk 1)
• Lomitapide inhibits microsomal triglyceride-transfer protein, reducing VLDL/LDL production independently of LDLR. It is used chiefly in adult HoFH; hepatic steatosis, transaminase elevation, diarrhea, drug interactions, and fat-soluble-vitamin deficiency require monitoring.
• Lipoprotein apheresis physically removes apoB lipoproteins and is often needed in severe HoFH, pregnancy, or refractory disease. The effect is immediate but rebounds between sessions; access, vascular burden, and cost are major limitations.
• Liver transplantation supplies functional hepatic LDLR but carries operative risk and lifelong immunosuppression; it is a last-resort intervention.

Genotype-guided care. Residual LDLR activity predicts response to statins and PCSK9-directed therapy. Null/null disease favors early LDLR-independent treatment—evinacumab, lomitapide, and/or apheresis. This is clinically actionable pharmacogenetic stratification, although it is not principally a drug-metabolism PGx effect.

Experimental therapies. LDLR replacement, mRNA/exosome delivery, in-vivo editing, and PCSK9/ANGPTL3 editing remain investigational. A recruiting phase III study, NCT06597006, is evaluating inclisiran in children aged 2–11 years with HoFH and documented biallelic null LDLR mutations; poor prior PCSK9-antibody response is an exclusion criterion. (NCT06597006 chunk 2)

13. Prevention

The pathogenic allele itself generally cannot be prevented after conception. Primary cardiovascular prevention comprises early diagnosis, no smoking, healthy diet/activity, blood-pressure and diabetes control, and lifelong LDL lowering. Secondary prevention is cascade/universal screening followed by treatment before symptoms. Tertiary prevention uses intensive combination therapy, apheresis, imaging, and management of established ASCVD to prevent recurrent events.

Genetic counseling should cover 50% transmission from an affected heterozygous parent, testing of first-degree relatives, reproductive partner testing when severe/founder disease is possible, and options for prenatal or preimplantation genetic testing when the familial variant is known. Vaccines and antimicrobial prophylaxis are not disease-specific interventions.

14. Other species and natural disease

LDLR orthologues and receptor-mediated LDL clearance are evolutionarily conserved. Naturally occurring Watanabe heritable hyperlipidemic rabbits carry LDLR deficiency and develop severe hypercholesterolemia and atherosclerosis, closely modeling human FH. LDLR-related hypercholesterolemia has also been described in rhesus monkeys and selected pigs. This is not infectious, transmissible, or zoonotic. Breed-level VBO assignment should be made only for a verified veterinary strain/breed record; the WHHL rabbit is principally a research strain rather than a common companion-animal breed. (ishibashi1993hypercholesterolemiainlow pages 1-2)

15. Model organisms

• Ldlr−/− mouse (NCBI Taxon 10090): viable and fertile; total cholesterol is approximately twofold wild type, IDL/LDL rises seven- to ninefold, VLDL and LDL half-lives are prolonged 30-fold and 2.5-fold, and hepatic adenoviral LDLR normalized elevated IDL/LDL within four days. Strengths are tractability, controlled diet, and atherosclerosis/gene-therapy studies. Limitations include apoB48-rich murine metabolism and limited spontaneous atherosclerosis on normal chow. Exact abstract quote: “The elevated IDL/LDL level of LDLR-/- mice was reduced to normal 4 d after the intravenous injection” of LDLR adenovirus. (ishibashi1993hypercholesterolemiainlow pages 1-2)
• WHHL rabbit (NCBI Taxon 9986): natural LDLR deficiency, LDL-rich profile, and early atherosclerosis; more human-like lipoprotein physiology than mice, but cost and genetic-tool availability are disadvantages.
• Ldlr-deficient hamster/pig: useful because CETP and apoB-lipoprotein biology are more human-like; applied to PCSK9/LDLR pharmacology and large-vessel imaging. Greater expense and lower throughput limit use.
• CRISPR LDLR-KO cynomolgus monkey (NCBI Taxon 9541): six animals had extremely high cholesterol/triglycerides, elevated VLDL/LDL, reduced HDL, poor drug response, and periocular xanthomas by one year, closely recapitulating HoFH. Exact abstract quote: “The levels of plasma cholesterol and triglyceride were quite high in the monkeys, and were similar to those in FH patients with homozygous mutations in the LDLR gene.” Limitations include small cohorts, mosaic/editing effects, ethics, cost, and short follow-up. (sato2023generationofa pages 1-2)
• Human cellular models: patient fibroblasts, hepatocyte-like cells, engineered LDLR-null hepatic lines, and iPSC-derived hepatocytes support LDL-binding/uptake, receptor-abundance, trafficking, VUS, and gene-correction assays. They do not reproduce multicellular plaque biology.

Recent developments and evidence interpretation

The most consequential 2023–2024 developments are implementation-focused IAS guidance, expanding pediatric PCSK9 evidence, pediatric and adolescent inclisiran programs, pediatric evinacumab development, and maturation of LDLR-independent and editing strategies. The expert consensus is that the central failure is no longer absence of effective LDL-lowering tools, but late detection, undertreatment, inequitable access, and failure to sustain sufficiently low LDL-C from childhood. Only about 10% of affected people are diagnosed, while most treated patients remain above recommended targets. (arnold2023familialhypercholesterolemiapitfalls pages 1-2, watts2023internationalatherosclerosissociety pages 1-2)

Selected authoritative sources

1. Watts GF et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, published June 2023; 20:845–869. DOI/URL: https://doi.org/10.1038/s41569-023-00892-0. (watts2023internationalatherosclerosissociety pages 1-2)
2. Arnold N, Koenig W. Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment. Reviews in Cardiovascular Medicine, August 2023. DOI/URL: https://doi.org/10.31083/j.rcm2408236. (arnold2023familialhypercholesterolemiapitfalls pages 1-2)
3. Chora JR et al. ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. Genetics in Medicine, February 2022;24:293–306. DOI/URL: https://doi.org/10.1016/j.gim.2021.09.012. (chora2022theclinicalgenome pages 1-3)
4. Xiao G et al. Efficacy and Safety of Evolocumab and Alirocumab…in Pediatric Patients with FH. Medicina, published 8 October 2024. DOI/URL: https://doi.org/10.3390/medicina60101646. (xiao2024efficacyandsafety pages 1-2)
5. Sato A et al. Generation of a familial hypercholesterolemia model in non-human primate. Scientific Reports, September 2023;13:15649. DOI/URL: https://doi.org/10.1038/s41598-023-42763-1. (sato2023generationofa pages 1-2)
6. Srivastava RAK. Targeting LDL receptor-dependent and-independent pathways… Cells, June 2023;12:1648. DOI/URL: https://doi.org/10.3390/cells12121648. (srivastava2023areviewof pages 8-9)

Evidence note. Exact PMIDs were not exposed for every retrieved article, so DOI URLs are supplied rather than risking incorrect PMID assignment. Trial facts derive from ClinicalTrials.gov records; mechanistic claims are distinguished above as human clinical, expert-guidance, cellular, or model-organism evidence.

References

1. (arnold2023familialhypercholesterolemiapitfalls pages 1-2): Natalie Arnold and Wolfgang Koenig. Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment. Reviews in Cardiovascular Medicine, Aug 2023. URL: https://doi.org/10.31083/j.rcm2408236, doi:10.31083/j.rcm2408236. This article has 16 citations and is from a peer-reviewed journal.

2. (chora2022theclinicalgenome pages 5-6): Joana R. Chora, Michael A. Iacocca, Lukáš Tichý, Hannah Wand, C. Lisa Kurtz, Heather Zimmermann, Annette Leon, Maggie Williams, Steve E. Humphries, Amanda J. Hooper, Mark Trinder, Liam R. Brunham, Alexandre Costa Pereira, Cinthia E. Jannes, Margaret Chen, Jessica Chonis, Jian Wang, Serra Kim, Tami Johnston, Premysl Soucek, Michal Kramarek, Sarah E. Leigh, Alain Carrié, Eric J. Sijbrands, Robert A. Hegele, Tomáš Freiberger, Joshua W. Knowles, and Mafalda Bourbon. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for ldlr variant classification. Genetics in Medicine, 24:293-306, Feb 2022. URL: https://doi.org/10.1016/j.gim.2021.09.012, doi:10.1016/j.gim.2021.09.012. This article has 179 citations and is from a highest quality peer-reviewed journal.

3. (watts2023internationalatherosclerosissociety pages 1-2): Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, and Raul D. Santos. International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, 20:845-869, Jun 2023. URL: https://doi.org/10.1038/s41569-023-00892-0, doi:10.1038/s41569-023-00892-0. This article has 294 citations and is from a domain leading peer-reviewed journal.

4. (chora2022theclinicalgenome pages 8-10): Joana R. Chora, Michael A. Iacocca, Lukáš Tichý, Hannah Wand, C. Lisa Kurtz, Heather Zimmermann, Annette Leon, Maggie Williams, Steve E. Humphries, Amanda J. Hooper, Mark Trinder, Liam R. Brunham, Alexandre Costa Pereira, Cinthia E. Jannes, Margaret Chen, Jessica Chonis, Jian Wang, Serra Kim, Tami Johnston, Premysl Soucek, Michal Kramarek, Sarah E. Leigh, Alain Carrié, Eric J. Sijbrands, Robert A. Hegele, Tomáš Freiberger, Joshua W. Knowles, and Mafalda Bourbon. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for ldlr variant classification. Genetics in Medicine, 24:293-306, Feb 2022. URL: https://doi.org/10.1016/j.gim.2021.09.012, doi:10.1016/j.gim.2021.09.012. This article has 179 citations and is from a highest quality peer-reviewed journal.

5. (ishibashi1993hypercholesterolemiainlow pages 1-2): S. Ishibashi, Michael S. Brown, J. Goldstein, R. Gerard, R. Hammer, and J. Herz. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. The Journal of clinical investigation, 92 2:883-93, Aug 1993. URL: https://doi.org/10.1172/jci116663, doi:10.1172/jci116663. This article has 2174 citations.

6. (arnold2023familialhypercholesterolemiapitfalls pages 4-6): Natalie Arnold and Wolfgang Koenig. Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment. Reviews in Cardiovascular Medicine, Aug 2023. URL: https://doi.org/10.31083/j.rcm2408236, doi:10.31083/j.rcm2408236. This article has 16 citations and is from a peer-reviewed journal.

7. (arnold2023familialhypercholesterolemiapitfalls pages 2-3): Natalie Arnold and Wolfgang Koenig. Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment. Reviews in Cardiovascular Medicine, Aug 2023. URL: https://doi.org/10.31083/j.rcm2408236, doi:10.31083/j.rcm2408236. This article has 16 citations and is from a peer-reviewed journal.

8. (sato2023generationofa pages 1-2): Akira Sato, Tomoyuki Tsukiyama, Masahiro Komeno, Chizuru Iwatani, Hideaki Tsuchiya, Ikuo Kawamoto, Mitsuru Murase, Takahiro Nakagawa, Iori Itagaki, Yasunari Seita, Shoma Matsumoto, Masataka Nakaya, Akio Shimizu, Atsushi Yamada, Masatsugu Ema, and Hisakazu Ogita. Generation of a familial hypercholesterolemia model in non-human primate. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42763-1, doi:10.1038/s41598-023-42763-1. This article has 9 citations and is from a peer-reviewed journal.

9. (xiao2024efficacyandsafety pages 1-2): Guoguang Xiao, Shan Gao, Yongmei Xie, Zhiling Wang, and Min Shu. Efficacy and safety of evolocumab and alirocumab as pcsk9 inhibitors in pediatric patients with familial hypercholesterolemia: a systematic review and meta-analysis. Medicina, 60:1646, Oct 2024. URL: https://doi.org/10.3390/medicina60101646, doi:10.3390/medicina60101646. This article has 10 citations.

10. (OpenTargets Search: familial hypercholesterolemia-LDLR): Open Targets Query (familial hypercholesterolemia-LDLR, 34 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

11. (srivastava2023areviewof pages 8-9): Rai Ajit K. Srivastava. A review of progress on targeting ldl receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ascvd. Cells, 12:1648, Jun 2023. URL: https://doi.org/10.3390/cells12121648, doi:10.3390/cells12121648. This article has 49 citations.

12. (chora2022theclinicalgenome pages 1-3): Joana R. Chora, Michael A. Iacocca, Lukáš Tichý, Hannah Wand, C. Lisa Kurtz, Heather Zimmermann, Annette Leon, Maggie Williams, Steve E. Humphries, Amanda J. Hooper, Mark Trinder, Liam R. Brunham, Alexandre Costa Pereira, Cinthia E. Jannes, Margaret Chen, Jessica Chonis, Jian Wang, Serra Kim, Tami Johnston, Premysl Soucek, Michal Kramarek, Sarah E. Leigh, Alain Carrié, Eric J. Sijbrands, Robert A. Hegele, Tomáš Freiberger, Joshua W. Knowles, and Mafalda Bourbon. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for ldlr variant classification. Genetics in Medicine, 24:293-306, Feb 2022. URL: https://doi.org/10.1016/j.gim.2021.09.012, doi:10.1016/j.gim.2021.09.012. This article has 179 citations and is from a highest quality peer-reviewed journal.

13. (NCT04233918 chunk 1): Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia. Regeneron Pharmaceuticals. 2020. ClinicalTrials.gov Identifier: NCT04233918

14. (chora2022theclinicalgenome pages 11-13): Joana R. Chora, Michael A. Iacocca, Lukáš Tichý, Hannah Wand, C. Lisa Kurtz, Heather Zimmermann, Annette Leon, Maggie Williams, Steve E. Humphries, Amanda J. Hooper, Mark Trinder, Liam R. Brunham, Alexandre Costa Pereira, Cinthia E. Jannes, Margaret Chen, Jessica Chonis, Jian Wang, Serra Kim, Tami Johnston, Premysl Soucek, Michal Kramarek, Sarah E. Leigh, Alain Carrié, Eric J. Sijbrands, Robert A. Hegele, Tomáš Freiberger, Joshua W. Knowles, and Mafalda Bourbon. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for ldlr variant classification. Genetics in Medicine, 24:293-306, Feb 2022. URL: https://doi.org/10.1016/j.gim.2021.09.012, doi:10.1016/j.gim.2021.09.012. This article has 179 citations and is from a highest quality peer-reviewed journal.

15. (srivastava2023areviewof pages 14-16): Rai Ajit K. Srivastava. A review of progress on targeting ldl receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ascvd. Cells, 12:1648, Jun 2023. URL: https://doi.org/10.3390/cells12121648, doi:10.3390/cells12121648. This article has 49 citations.

16. (watts2023internationalatherosclerosissociety pages 2-3): Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, and Raul D. Santos. International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, 20:845-869, Jun 2023. URL: https://doi.org/10.1038/s41569-023-00892-0, doi:10.1038/s41569-023-00892-0. This article has 294 citations and is from a domain leading peer-reviewed journal.

17. (arnold2023familialhypercholesterolemiapitfalls pages 7-8): Natalie Arnold and Wolfgang Koenig. Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment. Reviews in Cardiovascular Medicine, Aug 2023. URL: https://doi.org/10.31083/j.rcm2408236, doi:10.31083/j.rcm2408236. This article has 16 citations and is from a peer-reviewed journal.

18. (NCT03397121 chunk 1): Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH). The Medicines Company. 2017. ClinicalTrials.gov Identifier: NCT03397121

19. (NCT04652726 chunk 1): Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia. Novartis Pharmaceuticals. 2021. ClinicalTrials.gov Identifier: NCT04652726

20. (NCT03399786 chunk 1): Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. Regeneron Pharmaceuticals. 2018. ClinicalTrials.gov Identifier: NCT03399786

21. (NCT06597006 chunk 2): Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia. Novartis Pharmaceuticals. 2025. ClinicalTrials.gov Identifier: NCT06597006

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.